Cited 35 times in
A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 노재경 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 안중배 | - |
dc.contributor.author | 유내춘 | - |
dc.contributor.author | 정현철 | - |
dc.contributor.author | 정희철 | - |
dc.date.accessioned | 2015-06-10T13:01:47Z | - |
dc.date.available | 2015-06-10T13:01:47Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/110878 | - |
dc.description.abstract | This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-containing regimens. The initial dose of S-1 was 35 mg m−2, administered twice daily for 14 days every 3 weeks. Treatment was repeated until the occurrence of disease progression. Twenty-eight patients were enrolled. S-1 was administered to 21 patients as third-line therapy and to the remaining seven patients as fourth-line therapy. Of 26 evaluable patients, the overall response rate was 14.3% (95% CI, 0.4–28.1), and the disease control rate was 42.9% (95% CI, 23.3–62.4). With a median follow-up period of 227 days, median time to progression and overall survival duration were 91 and 414 days, respectively. The 1-year survival rate of all patients was 60.7%. There was no grade 4 toxicity. Grade 3 haematological toxicities were documented only in two patients. In conclusion, S-1 shows potential as a salvage regimen in heavily pretreated colorectal cancer patients. The twice-daily dose of 35 mg m−2 was well tolerated and can be used in designing further combination chemotherapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1637~1641 | - |
dc.relation.isPartOf | BRITISH JOURNAL OF CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Camptothecin/administration & dosage | - |
dc.subject.MESH | Camptothecin/analogs & derivatives | - |
dc.subject.MESH | Colorectal Neoplasms/drug therapy* | - |
dc.subject.MESH | Colorectal Neoplasms/pathology | - |
dc.subject.MESH | Colorectal Neoplasms/secondary | - |
dc.subject.MESH | Drug Combinations | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Irinotecan | - |
dc.subject.MESH | Liver Neoplasms/drug therapy* | - |
dc.subject.MESH | Liver Neoplasms/secondary | - |
dc.subject.MESH | Lung Neoplasms/drug therapy* | - |
dc.subject.MESH | Lung Neoplasms/secondary | - |
dc.subject.MESH | Lymphatic Metastasis/pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Recurrence, Local/drug therapy* | - |
dc.subject.MESH | Organoplatinum Compounds/administration & dosage | - |
dc.subject.MESH | Oxaliplatin | - |
dc.subject.MESH | Oxonic Acid/administration & dosage | - |
dc.subject.MESH | Salvage Therapy | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Tegafur/administration & dosage | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens | - |
dc.type | Article | - |
dc.contributor.college | Researcher Institutes (부설 연구소) | - |
dc.contributor.department | Cancer Metastasis Research Center (암전이연구센터) | - |
dc.contributor.googleauthor | H-C Jeung | - |
dc.contributor.googleauthor | S Y Rha | - |
dc.contributor.googleauthor | B C Cho | - |
dc.contributor.googleauthor | N C Yoo | - |
dc.contributor.googleauthor | J K Roh | - |
dc.contributor.googleauthor | W J Roh | - |
dc.contributor.googleauthor | H C Chung | - |
dc.contributor.googleauthor | J B Ahn | - |
dc.identifier.doi | 10.1038/sj.bjc.6603468 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01290 | - |
dc.contributor.localId | A02262 | - |
dc.contributor.localId | A02457 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A01316 | - |
dc.contributor.localId | A03794 | - |
dc.relation.journalcode | J00406 | - |
dc.identifier.eissn | 1532-1827 | - |
dc.identifier.pmid | 17106441 | - |
dc.subject.keyword | colorectal adenocarcinoma | - |
dc.subject.keyword | S-1 | - |
dc.subject.keyword | oxaliplatin-resistant | - |
dc.subject.keyword | irinotecan-resistant | - |
dc.contributor.alternativeName | Roh, Jae Kyung | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.alternativeName | Ahn, Joong Bae | - |
dc.contributor.alternativeName | Yoo, Nae Choon | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.alternativeName | Jeung, Hei Cheul | - |
dc.contributor.affiliatedAuthor | Roh, Jae Kyung | - |
dc.contributor.affiliatedAuthor | Ahn, Joong Bae | - |
dc.contributor.affiliatedAuthor | Yoo, Nae Choon | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Jeung, Hei Cheul | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 95 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1637 | - |
dc.citation.endPage | 1641 | - |
dc.identifier.bibliographicCitation | BRITISH JOURNAL OF CANCER, Vol.95(12) : 1637-1641, 2006 | - |
dc.identifier.rimsid | 54925 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.